Betoptic C eye drops 0.25% 5ml

Betoptic C (Betoptik) eye drops - is an antiglaucoma preparation from the group of selective beta-blockers that is used to reduce intraocular pressure in patients with increased eye pressure and open-angle glaucoma. Reduces eye pressure by reducing the production of intraocular fluid, and thus prevents the development of complications. As a rule, it is the drug of choice in the initial therapy of glaucoma.

Betoptic C eye drops - antiglaucoma preparation. Selective beta-1-adrenoblocker without internal sympathomimetic activity. Does not have membrane-stabilizing (local anesthetic) action.

With topical application, betaxolol reduces intraocular pressure by reducing the production of intraocular fluid.

The onset of hypotensive action is observed 30 minutes after instillation, the maximum effect develops after 2 hours. After a single instillation, the effect on the ophthalmotonus persists for 12 hours.

Betaxolol (in comparison with other beta-adrenoblockers) does not cause a decrease in blood flow in the optic nerve.

The use of Betoptics does not lead to the appearance of miosis, spasm of accommodation, hemeralopia, the effect of "swaddling" before the eyes (in contrast to myotics).

Indications:

The drug is used to reduce intraocular pressure as a monotherapy or in combination with other drugs with:

• Open angle glaucoma.
• Ocular hypertension.

Betoptic C can be used to treat open-angle glaucoma or ocular hypertension in patients with respiratory system diseases.

Contraindications:

• Hypersensitivity to the components of the drug.

With caution: should prescribe the drug with sinus bradycardia, AV-blockade II and III degree, severe heart failure, cardiogenic shock, myasthenia gravis, diabetes mellitus.

Special instructions:

Caution is prescribed to patients with diabetes mellitus, since beta-blockers may mask the symptoms of acute hypoglycemia.

With caution appoint the drug to patients with thyrotoxicosis, tk. beta-blockers may mask the symptoms of thyrotoxicosis (eg, tachycardia). Patients with suspected thyrotoxicosis should not abstain from beta-blockers, this can cause an increase in symptoms.

It should be borne in mind that beta-blockers can cause symptoms similar to those in myasthenia gravis (diplopia, ptosis, general weakness).

Caution should be given to beta-blockers in patients with severe impairment of the function of the respiratory system. Despite the fact that clinical studies have shown no effect of betaxolol on the function of external respiration, it is impossible to exclude the possibility of hypersensitivity to the drug.

Before the planned surgery, you should gradually cancel the beta-blockers 48 hours before the general anesthesia, tk. during general anesthesia, they can reduce the sensitivity of the myocardium to sympathetic stimulation.

Patients who use beta-blockers may have a history of atopy or anaphylactic reactions. In the case of the development of repeated reactions of hypersensitivity, such patients may not be sensitive to the usual doses of epinephrine (adrenaline) necessary for arresting anaphylaxis.

The drug should be administered with caution to patients with Reynaud's syndrome or pheochromocytoma.

When instilled in the eye, beta-blockers can be absorbed into the systemic circulation. In this case, the same side effects can be noted, as in systemic application. Cases of severe respiratory and cardiovascular disorders, including bronchospasm with fatal outcome in patients with bronchial asthma and death from heart failure are described.

Betoptik C has minimal impact on blood pressure and heart rate. However, care should be taken when prescribing the drug to patients with AV blockade or heart failure. Treatment Bethoptic should immediately stop when the first symptoms of decompensation from the cardiovascular system.

Care should be taken when combining Betoptik and adrenergic psychotropic agents together.

Eye drops of Betoptic contain preservatives that can precipitate in soft contact lenses and have a damaging effect on the eye tissue. Therefore, patients wearing contact lenses should be removed before using drops and installed back no earlier than 20 minutes after instillation.

Use in Pediatrics

A sufficient experience in the use of Betoptic in children is not available.

Impact on the ability to drive vehicles and manage mechanisms

If, after the application of droplets in patients, the visual clarity is temporarily reduced, it is not recommended to drive the car and engage in activities requiring increased attention and reaction before recovery.

Suggested Use:

1 ml of eye drops contains:

Active substances: betaxolol hydrochloride - 2,8 mg, which corresponds to the content of betaxolol - 2.5 mg.

Excipients: benzalkonium chloride, mannitol, carbomer 974P, polystyrene sulfonic acid, boric acid, disodium edetate, N-lauroyl sarcosine, hydrochloric acid and / or sodium hydroxide solution (to maintain the pH level), purified water.

Packaging:

• Comes in original packaging. Item is brand new and unopened.

Storage:

• Keep away from direct sunlight.
• Keep locked and away from children.
• Store in dry place at room temperature.
• Do not exceed storage temperature higher than 25 C

Important notice- the outer box design may vary before prior notice!